Hallux Inc.

Hallux Inc. is a healthcare company that develops innovative treatments for onychomycosis, focusing on a unique topical antifungal therapy that targets infections in the nail bed. Founded in 2012 and headquartered in Laguna Hills, US, Hallux Inc. specializes in treating onychomycosis.

The company has successfully completed 2 deals, with its most recent deal occurring on November 1, 2018. Hallux has raised a total of USD 7. 10 mn, including USD 1. 26 mn in its latest VENTURE DEBT round.

The firm was co-founded by Jay Birnbaum and Mark Taylor, the latter also serving as the CEO. Hallux Inc. specializes in the development of innovative treatments for onychomycosis, primarily through its core product, Hallux Subungual Gel (HSG). This topical antifungal therapy utilizes a novel delivery mechanism that targets the nail bed through the subungual space, an air gap accessible at the free edge of the toenail.

By leveraging this route of administration, HSG aims to provide effective therapeutic concentrations directly to the infection site, addressing a significant unmet need in the treatment of this common and often painful nail disorder. The company’s target clientele includes podiatrists and dermatologists who administer the treatment, thus serving the end users—patients suffering from onychomycosis—seeking effective relief from their condition. Hallux's products are anticipated to penetrate markets within the United States, where millions of individuals seek medical care for onychomycosis each year. Hallux Inc.

generates revenue through the distribution of its Hallux Subungual Gel (HSG) to healthcare professionals such as podiatrists and dermatologists. These clinicians facilitate the administration of the gel to patients, positioning Hallux as a provider in a business-to-business (B2B) transaction model. Revenue is derived from direct sales to these medical practices, with pricing strategies focused on making HSG a competitive alternative to oral antifungals, while also addressing the need for affordability in the market. Given the product's innovative application method and the rigorous studies corroborating its efficacy, Hallux is positioned to foster partnerships with healthcare providers, thus reinforcing its presence in the dermatological and podiatric treatment landscape.

As HSG progresses through clinical trials and regulatory approval processes, it is expected to enhance Hallux's market footprint and revenue potential. Hallux Inc. plans to utilize the USD 1. 26 mn raised in its most recent VENTURE DEBT financing to support the development of new products in the pipeline.

The company aims to expand into new markets within the United States, targeting specific regions where onychomycosis is prevalent. As HSG continues through its final stages of clinical trials and moves towards regulatory approval, Hallux anticipates launching the product within the next 12 to 18 months.